Target intelligence / Profile preview

Epithelial sodium channel subunit gamma (SCNN1G)

Target
SCNN1G
Molecular classification
Ion channel, Transporter (in context of epithelial sodium transport)
01

Overview

Epithelial sodium channel subunit gamma (SCNN1G) is a pore-forming subunit of the epithelial sodium channel (ENaC), an amiloride-sensitive, non-voltage-gated ion channel crucial for sodium reabsorption across epithelial tissues. The ENaC complex, assembled as a heterotrimer of alpha, beta, and gamma subunits, is essential for regulating sodium and water balance in the kidney, lung, and other epithelia, affecting blood volume and blood pressure. Mutations in SCNN1G cause rare monogenic hypertension (Liddle syndrome) and hypotension (pseudohypoaldosteronism type I) syndromes and contribute to common blood pressure variation and cardiovascular risk. ENaC function is targeted by drugs (notably amiloride) used to treat hypertension and fluid overload. The channel is regulated by hormones such as aldosterone and is expressed in tissues including kidney tubules, airway epithelia, distal colon, and taste buds, where it also plays a role in salt perception.

Other names
Sodium channel epithelial 1 subunit gammaAmiloride-sensitive sodium channel subunit gammaENaC subunit gammaENaCgammaGamma-ENaCNonvoltage-gated sodium channel 1 subunit gammaSCNEGBESC3LDLS2PHA1PHA1B3ENaCgENaCGGamma-NaCH
02

Mechanism of action

Blockade of sodium conductance via ENaC by direct binding (blocker/antagonist) – e.g., by amiloride

03

Biological functions

Electrolyte and fluid homeostasisSodium ion transportBlood pressure regulationRegulation of osmolaritySalt taste perception
04

Disease associations

Cardiovascular disease (hypertension, hypotension, blood pressure regulation)Monogenic syndromes (Liddle syndrome, Pseudohypoaldosteronism type I)Cystic fibrosis–like disorders (mucus clearance, airway hydration)BronchiectasisOther (altered salt/water balance in renal, pulmonary, and glandular pathology)
05

Safety considerations

Hyperkalemia risk with channel inhibition/blockadeElectrolyte disturbances (hyponatremia, hypovolemia) if inappropriately modulatedGenetic loss-of-function causes hypotension (pseudohypoaldosteronism) and gain-of-function causes hypertension (Liddle syndrome)
06

Interacting drugs

Amiloride

1 more in the full profile.

07

Biomarkers

SCNN1G peptide/protein/mRNA expression for diagnosis of Liddle syndrome and pseudohypoaldosteronismGenetic variants (e.g., SNPs such as rs13331086) for hypertension and blood pressure risk stratification

Beyond the preview

Go deeper on Epithelial sodium channel subunit gamma (SCNN1G).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epithelial sodium channel subunit gamma (SCNN1G).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call